Last Updated : May 4, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
N/A | enzalutamide | Genito-urinary cancer (prostate cancer) | Pending | |||
Spevigo | spesolimab | generalized pustular psoriasis (GPP) | Pending | |||
Alsitek | masitinib mesylate | Amyotrophic lateral sclerosis (ALS) | Suspended | |||
Myalepta | metreleptin | Leptin deficiency in lipodystrophy | Active | |||
Adtralza | tralokinumab | atopic dermatitis (AD) | Active | |||
Repatha | evolocumab | Primary hyperlipidemia | Active | |||
TBC | sotatercept | Pulmonary arterial hypertension (WHO group 1) | Active | |||
Remsima | infliximab | Crohn’s disease | Active | |||
Remsima | infliximab | Ulcerative Colitis | Active | |||
TBC | eplontersen | Polyneuropathy in hereditary transthyretin-mediated amyloidosis | Active |